
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection
Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : C1K
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : C1K is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : C1K
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
